Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$14.39
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.39
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$176.68M
Enterprise Value$91.17M
Total Cash (Recent Filing)$113.97M
Total Debt (Recent Filing)$42.88M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Aug 18, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.68
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue23.73
Enterprise Value/Gross Profit32.41
Enterprise Value/Ebitda-1.17
Forecast
1Y Price Target
$19.00Price Target Upside32.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$1.68M
Bulls Say, Bears Say
Bulls Say
Promising RNA-editing PipelineKRRO-111’s preclinical >90% SERPINA1 editing and ~90% restoration of functional M‑AAT in PiZZ mice signals a potentially best‑in‑class RNA editing therapeutic. Durable platform validation like this can attract partners, derisk the pipeline, and improve long‑term commercialization prospects if clinical translation succeeds.
Manageable LeverageModerate leverage (debt/equity ~0.36) and ~$183.6M in assets suggest the company retains balance sheet capacity to fund near‑term operations and R&D. This structural cushion provides flexibility for additional investment or strategic partnering before more dilutive financing becomes necessary.
Governance ContinuityShareholder approval of directors, executive compensation and appointment of Ernst & Young indicates governance stability and investor alignment. Stable oversight and continuity of external audit support consistent financial reporting and reduce execution risk as the company advances clinical programs over the medium term.
Bears Say
High Cash BurnSustained negative operating and free cash flow of roughly -$70M TTM materially erodes reserves and forces dependency on external financing or partnerships. Over several quarters this persistent burn raises dilution risk, limits ability to advance multiple programs simultaneously, and constrains strategic flexibility.
Weak And Shrinking RevenueVery low TTM revenue and a ~40% year‑over‑year decline mean limited internal funding from operations and little commercial validation. Structural revenue weakness increases reliance on capital markets or partners, reduces visibility into sustainable operations, and heightens execution risk for pipeline development.
Large Recurring Losses & Financing RiskPersistent large operating and net losses coupled with past balance‑sheet volatility (including a year of negative equity) indicate ongoing capital needs. This structural pattern pressures returns, increases the probability of future dilution, and means long‑term value depends heavily on successful clinical milestones or partnership deals.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $176.68M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Aug 18, 2026 which is in 30 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.727 by $0.037.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.34.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,422,571 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.727. Following the earnings report the stock price went down -3.373%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (32.04% Upside)
$19.00 (32.04% Upside)
Hedge Fund Trend
Increased
By 409.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-117.86%
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
KRRO Stock 12 Month Forecast
Average Price Target
$19.00
▲(32.04% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―